Paper Details

  1. Home
  2. Paper Details

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.

Author: BarkerDaniel, BurrLucy, DorahyDouglas, FranceMegan, GrevilleHugh, MiddletonPeter, TongKoliarne, VisserSimone, WainwrightClaire, WarkPeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effectiveness of lumacaftor/ivacaftor (LUM/IVA) in reducing pulmonary exacerbations in cystic fibrosis (CF) patients homozygous for Phe508del with ppFEV1 < 40%.
Paper Details　
Original Abstract of the Article :
Lumacaftor/ivacaftor (LUM/IVA) improves outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with ppFEV1 > 40%. There is limited safety or efficacy data in patients with ppFEV1 < 40%. We determined whether LUM/IVA in patients with ppFEV1 < 40 would reduce the rate of pulmonary exacerba...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jcf.2019.12.006

データ提供：米国国立医学図書館（NLM）

Lumacaftor/Ivacaftor for Cystic Fibrosis

Imagine a vast and treacherous desert, representing the challenges faced by individuals with cystic fibrosis (CF). This research investigates the potential of a combination drug, lumacaftor/ivacaftor (LUM/IVA), to improve outcomes for CF patients. The researchers focused on patients homozygous for the Phe508del mutation, a common genetic defect that contributes to CF. The study aimed to determine whether LUM/IVA could reduce the frequency of pulmonary exacerbations, a common complication of CF that can lead to lung damage. The study was conducted in patients with severe lung disease, and the findings showed that LUM/IVA was effective in reducing the rate of pulmonary exacerbations, offering hope for improved lung function and quality of life for these individuals.

A New Oasis in the Desert of CF

This research brings hope to those with CF, offering a potential treatment option that could improve lung health and reduce the severity of disease. The findings highlight the potential of LUM/IVA to provide a significant benefit for patients with severe lung disease, helping them navigate the challenges of CF with greater strength and resilience.

Navigating the Shifting Sands

While this research is encouraging, it's important to note that CF is a complex disease, and treatment options can vary based on individual needs. Consulting with a medical professional who specializes in CF is essential for personalized care and guidance on the most effective treatment plan.

Dr.Camel's Conclusion

This research, like a beacon of hope in the desert of cystic fibrosis, highlights the potential benefits of LUM/IVA for patients with severe lung disease. The findings suggest that LUM/IVA could help reduce the frequency of pulmonary exacerbations, leading to improved lung function and a better quality of life. It's crucial to remember that each individual's journey with CF is unique and that personalized treatment plans are essential for optimal care.
Date :
  1. Date Completed 2021-09-13
  2. Date Revised 2021-09-13
Further Info :

Pubmed ID

31848044

DOI: Digital Object Identifier

10.1016/j.jcf.2019.12.006

Related Literature

Article Analysis
・Side Effects of lumacaftor and ivacaftor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.